ArticleHypertension (Dallas, Tex. : 1979)2026
Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction.
Jean W Wassenaar, C Duncan Smart, Daniel J Fehrenbach, Megan M Shuey, Pranoy Sangowdar, Lin Zhong, Francis J Miller, Quinn S Wells, Shi Huang, Sean P Collins and 5 more
Abstract read
In one paragraphArticle in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Jean W WassenaarDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2835-6338 Daniel J FehrenbachDepartment of Medicine, Indiana University School of Medicine, Indianapolis (D.J.F., M.S.M.).ORCID 0000-0003-3382-464X Megan M ShueyDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2866-3562 Lin ZhongDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2550-3758 Francis J MillerDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-5822-0549 Quinn S WellsDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3899-0313 Shi HuangDepartment of Biostatistics (S.H.), Vanderbilt University Medical Center, Nashville, TN.
Sean P CollinsDepartment of Emergency Medicine (S.P.C., A.B.S., K.F.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2305-9836 Alan B StorrowDepartment of Emergency Medicine (S.P.C., A.B.S., K.F.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2893-808X Karen F MillerDepartment of Emergency Medicine (S.P.C., A.B.S., K.F.M.), Vanderbilt University Medical Center, Nashville, TN.
Deepak K GuptaDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2191-3485 Amanda C DoranDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-1576-6274 Meena S MadhurDepartment of Medicine, Indiana University School of Medicine, Indianapolis (D.J.F., M.S.M.).ORCID 0000-0002-0407-634X Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4MBuilding Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3MImproving Diagnostic Accuracy for Acute Heart FailureR01HL153607 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COLLINS, SEAN PATRICK, GUPTA, DEEPAK · 2021 to 2024
$5.9MCritical Mediators of Inflammation Resolution and Immune Memory in AtherosclerosisR01HL159487 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DORAN, AMANDA C · 2021 to 2025
$3.2MTissue Sodium, Inflammation, and Blood Pressure in MESAR01HL133860 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GUPTA, DEEPAK, TITZE, JENS MARC · 2016 to 2019
$2.7MImmune Modulation in HypertensionR01HL161212 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MADHUR, MEENAKSHI SWAMINATHAN · 2022 to 2025
$2.4MHypertension-associated Trained Immunity in Myeloid Cells is a Determinant of AtherosclerosisR01HL174961 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JONATHAN David BROWN, AMANDA C DORAN · 2025 to 2026
$1.5MAutomated Storage and Retrieval of Biological SystemsS10RR025141 · NCRR · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2008 to 2008
$988kNovel role of ROCK2 in Immune Mechanisms of Takotsubo CardiomyopathyK99HL177309 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Daniel J Fehrenbach · 2025 to 2026
$248kLeica Bond RXS10OD023475 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOYD, KELLI L. · 2018 to 2018
$213kAmerican Heart Association-American Stroke Association 24CDA1278132NCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA068485NCRR NIH HHS S10 RR025141NHLBI NIH HHS F30 HL151069NHLBI NIH HHS K99 HL177309NHLBI NIH HHS R01 HL133860NHLBI NIH HHS R01 HL153607NHLBI NIH HHS R01 HL159487NHLBI NIH HHS R01 HL161212NHLBI NIH HHS R01 HL174961NICHD NIH HHS K12 HD043483NIGMS NIH HHS T32 GM007569NIH HHS S10 OD023475
6 · The paper itselfAbstract
backgroundThe immune system is emerging as a key player in driving cardiac remodeling in heart failure with preserved ejection fraction (HFpEF). Galectin-1 (
methodsGalectin-1 was measured using the Olink proximity extension assay in human cohorts. HFpEF was induced in mice with myeloid-specific and global deletion of galectin-1 and corresponding controls using the hypertensive deoxycorticosterone acetate-salt model.
resultsPlasma galectin-1 was higher in both a preclinical model of HFpEF (
conclusionsGreater circulating galectin-1 levels are associated with a higher risk of incident heart failure and higher NT-proBNP among patients with acute HFpEF. However, neither global nor myeloid deficiency of galectin-1 altered the cardiovascular phenotype in a preclinical model of HFpEF, suggesting that it is a marker but not a causal mediator of the disease.
Indexed as
Galectin 1Heart FailureStroke VolumeAgedAnimalsBiomarkersDisease Models, AnimalFemaleHumansMaleMiceNatriuretic Peptide, BrainPeptide FragmentsBiomarkersGalectin 1Natriuretic Peptide, BrainPeptide Fragmentsgalectin-1heart failureinflammationmacrophages
Identifiers
PMID41614247
PMCPMC12879785
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390